http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013119512-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013119512-A |
| titleOfInvention | ANTIGENIC COMPOSITION AND ITS THERAPEUTIC APPLICATION FOR PREVENTION AND TREATMENT OF ONCOLOGICAL DISEASES, RECOMBINANT PLASMID DNA, PROVIDING SYNTHESIS OF HYBRID PROTEIN WHITE AND WHITE |
| abstract | 1. Recombinant plasmid DNA pPRAME-F or pPRAME-N or pPRAME-C, providing biosynthesis of the hybrid proteins PRAME-F, PRAME-N and PRAME-C, having a size of 7232, 6362 and 6566 bp, which is a vector pET containing the T7 promoter, ampicillin resistance gene, replicative pUC ori origin, lac inducer encoding gene, leader sequence encoding six histidine residues, enterokinase recognition site sequence and sequences necessary for successful translation of the recombinant protein in E. coli cells in which between BamH I and NdeI restriction enzyme sites are integrated into the reading frame of the cDNA gene of the corresponding fusion protein. 2. A vaccine composition for the prevention and treatment of cancer, containing a diluent and antigenic component in an effective amount, characterized in that as the latter it contains individual hybrid proteins PRAME-F, PRAME-N and PRAME-C obtained using plasmid DNA according to claim 1 or mixtures thereof. 3. The vaccine composition according to claim 2, which is in the form dried by spray drying, or vacuum drying, or lyophilization. 4. The vaccine composition according to claim 2, where the diluted composition contains an adjuvant. The vaccine composition according to claim 2, wherein the adjuvant is selected from an oil in water emulsion, 3D-MPL, CpG, aluminum salts, or a mixture of two or more of them. The method of obtaining hybrid proteins that are part of the vaccine composition according to claim 2, by expressing their genes as part of recombinant vectors in E. coli followed by purification of the target protein, characterized in that gene expression is carried out as part of the recombinant plasmid DNA according to claim 5, E. coli cells are cultured to a density of 0.8-1 OD, after four |
| priorityDate | 2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.